IQVIQVHealthcare · Diagnostics & Research

IQV Stock Forecast: IQVIA Holdings, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$246
−1.79% on the day

The 20 Wall Street analysts covering IQVIA Holdings, Inc. hold a median 12-month price target of $310 — +26.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 83 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$40.5B
Ticker Nerd rank
83/ 100
Median analyst target
$310
Analysts covering
20
Revenue$4.4B+8.7% y/y
Operating income$569.0M
Net income$258.0M
Free cash flow$360.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.2%
1M
−8.1%
YTD
+9.2%
1Y
+13.3%
From 52W high
−11.9%
From 52W low
+57.1%
$157
$279
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores IQVIA Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
83/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
87
Volatility
86
Momentum
81
Revisions
74
Growth
70
Issuance
62
Quality
62
Accruals
62

Value (87): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (62): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

IQV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IQV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$150$200$250$300$350Jan 26Apr 26Jul 26Oct 26IQVHigh $346Median $310Low $268

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says20 analysts
18
Buy
2
Hold
0
Sell
$268
Low
$310
Median
$346
High

The green dot is the last close — the median target sits +26.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 18 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
29 Oct 2026TD CowenMaintainsBuy$288 → $307
28 Oct 2026BairdMaintainsOutperform$324 → $328
28 Oct 2026Evercore ISI GroupMaintainsOutperform$290 → $310
28 Oct 2026JP MorganMaintainsOverweight$295 → $325
28 Oct 2026Truist SecuritiesMaintainsBuy$329 → $346
14 Oct 2026StifelMaintainsBuy$276 → $303
7 Oct 2026BarclaysMaintainsOverweight$275 → $300
7 Oct 2026MizuhoMaintainsOutperform$275 → $300
30 Sept 2026UBSReinstatesBuy$345
29 Sept 2026RBC CapitalMaintainsOutperform$247 → $319
28 Sept 2026Truist SecuritiesReiteratesBuy$300 → $329
17 Sept 2026Morgan StanleyMaintainsEqual-Weight$240 → $270
29 July 2026BairdMaintainsOutperform$252 → $287
29 July 2026BMO CapitalMaintainsOutperform$210 → $270
29 July 2026JP MorganMaintainsOverweight$225 → $285
29 July 2026RBC CapitalMaintainsOutperform$221 → $247
29 July 2026StifelMaintainsBuy$220 → $276
29 July 2026TD CowenMaintainsBuy$233 → $288
13 July 2026MizuhoMaintainsOutperform$215 → $230
1 July 2026BairdMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for IQV.

Market Radar

This page is one stock. Monday covers all of them.

IQV appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

IQV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, IQVIA Holdings, Inc. returned +13.3% against +6.9% for the S&P 500, dividends included.

IQV vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120130Jan 26Apr 26Jul 26Oct 26IQVS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IQV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−0.0%
Analysts raising
9
Analysts cutting
7
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
29.9×

Cheaper than 29% of US stocks

Price / sales
2.3×

Cheaper than 44% of US stocks

Price / book
6.1×

Cheaper than 14% of US stocks

EV / EBITDA
17.5×

Cheaper than 26% of US stocks

Growth & margins
Revenue growth (YoY)
8.0%

Higher than 48% of US stocks

Earnings growth (YoY)
5.7%

Higher than 44% of US stocks

Gross margin
32.9%

Higher than 38% of US stocks

Operating margin
13.9%

Higher than 71% of US stocks

Net margin
8.1%

Higher than 63% of US stocks

Returns & dividend
Return on equity
21.4%

Higher than 82% of US stocks

Return on assets
5.1%

Higher than 76% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • IQVIA Holdings, Inc. has a market value of $40.5B and an enterprise value of $54.5B.

  • Revenue in the twelve months to 30 June 2026: $17.0B. The latest quarter grew 8.7% year on year.

  • Net income over the same four quarters: $1.4B, a 8.1% net margin.

  • Diluted earnings per share, trailing twelve months: $8.06.

  • Free cash flow in the twelve months to 30 June 2026: $2.2B.

  • IQVIA Holdings, Inc. spent $1.2B on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 164.6M.

  • Trailing P/E: 29.9×; forward P/E: 17.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • IQVIA Holdings, Inc. employs 95,000 people — $179K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

IQV and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
IQVIQVIA Holdings, Inc.$40.5B83
NTRANatera, Inc.$39.6B70
WATWaters Corp.$43.2B52
MTDMettler-Toledo International, Inc.$34.1B96
AAgilent Technologies, Inc.$48.3B85
LHLabcorp Holdings, Inc.$30.4B88
IDXXIDEXX Laboratories, Inc.$54.0B91

Take a look at IQV’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own IQVIA Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about IQV

What is the IQV stock price forecast for 2026-2027?

The 20 Wall Street analysts covering IQVIA Holdings, Inc. have a median 12-month price target of $310, with estimates ranging from $268 to $346. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IQV stock a buy right now?

Of the 20 analysts covering IQVIA Holdings, Inc., 18 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks IQVIA Holdings, Inc. 83 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IQV?

As at 21 Nov 2026, IQVIA Holdings, Inc. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (87 of 100).

Will IQV stock go up?

No one can know that. What the data says: the median 12-month target from 20 analysts implies +26.0% from the last close, and Ticker Nerd's factor model ranks IQVIA Holdings, Inc. 83 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IQV stock forecast for 2030?

No analyst covering IQVIA Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IQV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $268 to $346 over the next 12 months.

How has IQV stock performed over the past year?

IQVIA Holdings, Inc. returned +13.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does IQVIA Holdings, Inc. do?

IQVIA Holdings Inc. is a global healthcare services and analytics company that supports the life sciences industry with clinical research services, commercial insights, and healthcare intelligence. The company combines advanced data, technology solutions, and domain expertise to help pharmaceutical, biotechnology, medical device, and healthcare organizations improve clinical development, evidence generation, and commercial execution.

Company

About IQVIA Holdings, Inc.

IQVIA Holdings Inc. is a global healthcare services and analytics company that supports the life sciences industry with clinical research services, commercial insights, and healthcare intelligence. The company combines advanced data, technology solutions, and domain expertise to help pharmaceutical, biotechnology, medical device, and healthcare organizations improve clinical development, evidence generation, and commercial execution. Its core business spans technology and analytics solutions, research and development solutions, and contract sales and medical solutions, making it a key partner across the medical product lifecycle. IQVIA Holdings Inc. serves clients in major regions worldwide, including the Americas, Europe, Africa, and the Asia-Pacific, and plays an important role in turning health data into actionable insights for research, operations, and market access.

CEO Mr. Ari Bousbib · 95,000 employees · United States · https://www.iqvia.com